HeartSciences Q1 FY27 net loss $3.2M; Fortitude merger closing in Q4 2026

HeartSciences Inc.

Net loss $3.2M in FQ1 2027 (ended 7/31/26) vs $2.1M year-ago; operating loss $2.9M; no meaningful revenue.
All-stock merger with Fortitude (Zcash mining) expected to close Q4 2026; Fortitude added 9,000 Z15 Pro miners (~7.5 Gsol/s) and a 12.5MW Nebraska facility.
MyoVista Insights platform: first US commercial agreements, version 1.4, selected by major European reference center; patent portfolio >45 granted.
Recorded $0.3M inventory reserve for MyoVista wavECG device; no further commercialization planned; FDA 510(k) still under review.
Since period end: raised ~$1.0M from Fortitude, ~$1.2M net ATM, exchanged $200K note for shares; shareholders' deficit $2.0M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.